Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN-Brachyury IV in Advanced Cancer
NCT04134312Phase 1Completed
- Sponsor
- Bavarian Nordic
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVA-BN-Brachyury in solid tumor, sponsored by Bavarian Nordic. Primary endpoint: Dose Limiting Toxicity. Started Jan 2020; status: completed.
02
Drugs
MVA-BN-Brachyury
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04134312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134312.